Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
火曜日, 8 25

Werewolf Therapeutics Inc

HOWLNASDAQ
Trade with Public
Trade with Public
$0.8833
0.00981.12%
近くで: Aug 21, 5:00 PM EST
$0.8550
-0.0185-2.12%
プレマーケット: 5:03 AM EST
M&A: Ambros Therapeutics, Inc announced it will be merged with Werewolf Therapeutics (HOWL) on Friday, August 21, 2026 for $47.5M paid in stock
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Werewolf Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Werewolf Therapeutics (HOWL).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

1S.Buy
3Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+660.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Dec 19, 2025HC Wainwright & Co.Andres Y. MaldonadoPT CutBuy$10→$4
Nov 18, 2025B of A SecuritiesJason ZemanskyPT CutBuy$8→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $8 to $7.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $9 to $8.
Benzinga Newsdesk

PRO
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and maintains $8 price target.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved